Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study will enroll patients who have metastatic pancreatic cancer and have progressed on
prior chemotherapy.
Part 1 (dose escalation) participants will receive
epacadostat/pembrolizumab/cyclophosphamide(CY)/GVAX pancreas vaccine followed by
epacadostat/pembrolizumab/CRS-207, Part 1X (dose escalation) participants will receive
epacadostat/pembrolizumab/CRS-207. Part 2X (dose expansion) participants will receive
epacadostat/pembrolizumab/CRS-207.
The primary objectives of this study are to determine the recommended dose of epacadostat in
this combination and assess survival of subjects in both treatment groups.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins